VANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Research and Development Corporation (“SaNOtize” or “the company”) announced that it has received approval from Health Canada to proceed with enrollment of volunteers in Phase III trials following earlier positive Phase II results for its Nitric Oxide Nasal Spray (NONS) for the prevention and early treatment of COVID-19 and its variants.

Register here.